Norgine

Norgine is a European specialist pharmaceutical company with a robust infrastructure for the development, manufacture, and commercialization of specialty pharmaceutical products. With a direct presence in all major European markets, Norgine focuses on delivering transformative medicines that enhance healthcare systems and patient outcomes. The company operates third-party supply networks and possesses significant product development capabilities, supported by a comprehensive sales and marketing infrastructure. This enables Norgine to provide clients with access to quality products in a cost-effective manner, ultimately adding value to the healthcare sector. With over 110 years of experience in the pharmaceutical industry, Norgine is dedicated to improving patient care through innovative solutions.

Juán Alcántara

CEO

Saulo Martiniano

COO

Peter Stein

Chairman

23 past transactions

Impress

Series B in 2022
Impress specializes in invisible orthodontics. They provide teeth alignment services intended to carry out a personalized diagnosis and treatment for each patient. The company provides services for unbalanced bites, crowded teeth, rotations, and interdental spaces and also offers individualized digital monitoring services.

Inovus Ltd

Venture Round in 2022
Inovus Ltd is a company based in Saint Helens, United Kingdom, that specializes in designing and manufacturing medical simulation products aimed at enhancing surgical training. Founded in 2012, the company offers a variety of simulators, including take-home laparoscopic simulators and institutional models, which focus on essential surgical techniques such as laparoscopic appendectomy and cholecystectomy. Inovus Ltd's products are tailored for surgical trainees and residents, providing them with accessible and versatile training options that improve their skills in critical care, medicine, and surgery. The company's commitment to advancing surgical education enables clinicians to deliver better patient care through improved training resources.

Magentiq Eye

Convertible Note in 2021
Magentiq Eye Ltd. is a medical device company based in Haifa, Israel, established in 2014. It specializes in developing advanced technologies for endoscopic procedures, particularly focusing on automatic polyp detection during colonoscopies. The company's flagship product, the Automatic Polyp Detection System (APDS), leverages deep learning and computer vision to enhance the accuracy of polyp identification, thereby reducing the miss rate during examinations. The APDS is available in two formats: APDS-RT, which operates in real-time by processing video feeds from endoscopic cameras, and APDS-OFL, which analyzes pre-recorded colonoscopy videos. Given the prevalence of colonoscopies—approximately 40 million performed annually—the system aims to improve patient outcomes by increasing detection rates and minimizing the risk of interval cancers. Magentiq Eye's technology not only supports physicians in making more informed decisions during procedures but also has the potential for integration with existing endoscopic equipment or as a service model for clinics and hospitals.

ImaginAb

Venture Round in 2021
ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of imaging agents and radiopharmaceutical therapy (RPT) products through its proprietary minibody and cys-diabody platforms. The lead candidate 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent is currently in Phase II clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within their immunotherapy clinical trials, primarily in oncology.

Azanta

Acquisition in 2020
Azanta is markets and distributes pharmaceutical products. Its products include Amnisure, Cicatridina, Repadina Plus, Cystistat, Flexi-T, Methadone, Oxandrin, Suplasyn, and development products.

Magentiq Eye

Series A in 2019
Magentiq Eye Ltd. is a medical device company based in Haifa, Israel, established in 2014. It specializes in developing advanced technologies for endoscopic procedures, particularly focusing on automatic polyp detection during colonoscopies. The company's flagship product, the Automatic Polyp Detection System (APDS), leverages deep learning and computer vision to enhance the accuracy of polyp identification, thereby reducing the miss rate during examinations. The APDS is available in two formats: APDS-RT, which operates in real-time by processing video feeds from endoscopic cameras, and APDS-OFL, which analyzes pre-recorded colonoscopy videos. Given the prevalence of colonoscopies—approximately 40 million performed annually—the system aims to improve patient outcomes by increasing detection rates and minimizing the risk of interval cancers. Magentiq Eye's technology not only supports physicians in making more informed decisions during procedures but also has the potential for integration with existing endoscopic equipment or as a service model for clinics and hospitals.

PathoQuest

Series A in 2019
PathoQuest SAS, a spin off of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improving the breadth of pathogen detection. The company’s proprietary next generation sequencing (NGS) based testing approach delivers actionable reports to clinicians, biologists and biopharmaceutical quality assurance managers/production managers. PathoQuest’s proprietary sample preparation, and its comprehensive database of pathogens genomic information, enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection. PathoQuest’s Viral Safety testing service, directed towards biopharmaceutical companies, is the company’s first commercial application of its testing approach and has quickly established a revenue stream for the company from several major biopharma companies.

SpineGuard

Post in 2018
SpineGuard is a French medical company focused on the design and production of innovative instruments for spinal surgeries. Its core technology, Dynamic Surgical Guidance (DSG®), provides a powerful, radiation-free real-time sensing platform that enhances the accuracy of skeletal implant placement. The company's flagship products, PediGuard probes, are handheld tools that assist spine surgeons in creating pilot holes in vertebrae prior to pedicle screw placement. These devices utilize an electrical conductivity measurement sensor to provide immediate feedback to surgeons regarding changes in bone and tissue composition, eliminating the need for X-ray imaging. SpineGuard’s products are applicable across a range of patient demographics, from pediatric cases involving deformity corrections to adults requiring internal fixation for degenerative conditions. The PediGuard line includes various designs to accommodate different surgical needs. Additionally, the DSG® Connect App enables the collection and visualization of data during procedures. With over 80,000 successful spinal surgeries supported by its technology and significant clinical evidence affirming its effectiveness, SpineGuard is positioned to address critical challenges in spinal surgery.

Magentiq Eye

Seed Round in 2018
Magentiq Eye Ltd. is a medical device company based in Haifa, Israel, established in 2014. It specializes in developing advanced technologies for endoscopic procedures, particularly focusing on automatic polyp detection during colonoscopies. The company's flagship product, the Automatic Polyp Detection System (APDS), leverages deep learning and computer vision to enhance the accuracy of polyp identification, thereby reducing the miss rate during examinations. The APDS is available in two formats: APDS-RT, which operates in real-time by processing video feeds from endoscopic cameras, and APDS-OFL, which analyzes pre-recorded colonoscopy videos. Given the prevalence of colonoscopies—approximately 40 million performed annually—the system aims to improve patient outcomes by increasing detection rates and minimizing the risk of interval cancers. Magentiq Eye's technology not only supports physicians in making more informed decisions during procedures but also has the potential for integration with existing endoscopic equipment or as a service model for clinics and hospitals.

Caresyntax

Venture Round in 2017
Caresyntax Inc. is a Boston-based company that provides a digital surgery platform designed to enhance surgical performance and improve patient outcomes. The platform integrates various data sources, including video, audio, and clinical information, to deliver actionable insights for operating room (OR) teams. By leveraging advanced analytics and IoT technology, Caresyntax enables healthcare organizations to benchmark surgical outcomes, optimize resource utilization, and reduce variability in clinical performance. The software is utilized in over 4,000 operating rooms globally, supporting more than 30,000 surgeons and impacting the care of over 2 million patients each year. The company offers solutions that facilitate real-time reporting and workflow automation, allowing hospitals to mitigate risks and improve surgical training without the extensive investment typical of traditional big data analytics. Founded in 1991, Caresyntax continues to advance the use of technology in healthcare to drive better surgical practices and outcomes.

Eyetronic Therapie

Venture Round in 2017
EBS Technologies is a medical device company that has developed a stimulation system for the treatment of neurologically caused impairments such as visual field loss. Such impairments can be the result of stroke, traumatic-brain-injury, glaucoma or several other diseases. The EBS Therapy (previously: NEXT WAVE™Therapy) is a non-invasive optic nerve stimulation deploying weak electrical currents, resulting in neuroregeneration and neuroprotection. Low-voltage electrical pulses are administered at frequencies and amplitudes identified as optimal for each patient, allowing retinal ganglion cells to regenerate and branch out new axons. The company benefits from more than 15 years of research and clinical experience with more than 1,200 patients. Double blind, randomized studies, as well as clinical observations show that the EBS Therapy can partially restore vision field in patients. In 2013 EBS Technologies received the CE Mark for the stimulation device and started the commercial treatment in 2014. There are currently 8 EBS Treatment centers across Germany and the company is slowly widening the network.

Merus Labs

Acquisition in 2017
The Merus corporate growth strategy is driven by a product acquisition plan which employs an opportunistic approach to source product acquisition candidates. This approach allows Merus to source pharmaceutical products across broad therapeutic classes which provides access to acquisition targets not available to other players and creates a diversified strategy. Although Merus has a broad therapeutic focus, opportunities will be pursued if the application of a dedicated small scale sales force can deliver incremental product sales growth. The geographic focus will be the United States and Canada

Collagen Solutions

Post in 2017
Collagen Solutions Plc is a global provider of medical grade collagen formulations and components for use in regenerative medicine, medical devices and in-vitro diagnostics. Our capabilities include the provision of native, soluble and powdered collagen formulations and expertise in the development and contract manufacture of collagen components for use as tissue scaffolds and medical devices. Collagen Solutions' unique offering extends beyond material supply and contract services as our highly skilled staff support customers through various stages of development and regulatory approval, establishing long-term commercial relationships.

PulseCath

Venture Round in 2016
PulseCath is a medical device company, develops, manufactures, and markets circulatory support systems to cardiologists and cardiac surgeons in the Netherlands and internationally. It offers iVAC 3L, a mid-range minimal heart circulatory assist device that generates up to three liters per minute, and offers critical hemodynamic support in the case of left ventricular failure or during high-risk revascularization procedures with potential post cardiotomy weaning complications.

Q3 Medical Devices

Venture Round in 2016
Q3 Medical Devices Limited is an Irish based holding company with multiple operations in Germany. The holding and its companies are focused on the development, manufacturing, and distribution of minimally invasive devices for the treatment of patients with cardiology, peripheral vascular and non-vascular diseases. Q3 Medical Devices Limited was formed by a global group of entrepreneurs, manufactures, distributors, industry doctors, and investors focused on the development and acquisition of medical device businesses with annual revenues between 1 -10 Million. The acquisitions are targeted in areas that expand the groups manufacturing base and capabilities, growth of its distribution channels, and accelerating its products offering focused on the minimally invasive treatment of patients with cardiology, peripheral vascular and non-vascular diseases.

SpineVision

Venture Round in 2014
SpineVision S.A. is a spinal technology company that specializes in the design, development, and marketing of implants and instrumentation for spinal treatment. Established in 1999 and headquartered in Antony, France, with subsidiaries in Belgium, Italy, the United Kingdom, and the United States, the company focuses on addressing a diverse range of spinal pathologies, including degenerative disc disease, deformities, cervical disorders, trauma, and tumors. Its product portfolio includes advanced systems such as Flex+, X-PLUS, LUMIS, and P.L.U.S., which offer various stabilization options and surgical solutions. Additionally, SpineVision provides specialized systems like the C3 anterior cervical plate and UNI-Thread, enhancing surgical procedures and outcomes. The company's innovations are developed in collaboration with prominent neurological and orthopedic surgeons, resulting in over 20 patents that reflect its commitment to advancing spinal care.

Azanta

Venture Round in 2014
Azanta is markets and distributes pharmaceutical products. Its products include Amnisure, Cicatridina, Repadina Plus, Cystistat, Flexi-T, Methadone, Oxandrin, Suplasyn, and development products.

Agendia

Debt Financing in 2014
Agendia, Inc. is a biotechnology company based in Irvine, California, founded in 2003. The company specializes in developing and distributing genomic-based diagnostic kits aimed at improving cancer treatment for patients. Agendia's molecular diagnostic technology offers insights into a patient's genomic profile, allowing physicians to make informed decisions regarding personalized treatment plans. The company's breast cancer tests utilize a comprehensive analysis of the human genome to evaluate individual risks for metastasis and determine the most appropriate therapies. This includes identifying which patients would benefit from chemotherapy or hormonal treatments, as well as those who may avoid more aggressive interventions in favor of less intensive and cost-effective options.

SuperSonic Imagine

Venture Round in 2014
SuperSonic Imagine SA is a medical technology company that specializes in developing and manufacturing advanced ultrasound imaging systems. Founded in 2005 and headquartered in Aix-en-Provence, France, the company is renowned for its Aixplorer system, which provides high-definition imaging and is particularly effective in diagnosing and monitoring breast, prostate, and thyroid cancers, as well as liver diseases. The Aixplorer system incorporates ShearWave technology, enabling quantitative elastography that measures tissue elasticity. SuperSonic Imagine operates primarily in markets such as China, the United States, and various European countries, distributing its products through a network of offices and distributors. As a subsidiary of Hologic Hub Ltd, the company continues to innovate in the field of medical imaging, enhancing the capabilities of healthcare professionals.

Stanmore Implants

Debt Financing in 2013
Stanmore Implants Worldwide is an innovative orthopaedic business focused on the design and manufacture of both bespoke and modular implants for limb-sparing and complex primary and revision joint replacement. Stanmore Implants Worldwide designs, manufactures and markets a custom implant service alongside a portfolio of orthopaedic implants for limb salvage and complex joint replacement, and is known for creating some of the world's most successful implants. Stanmore Implants Worldwide acquired its robotic bone preparation technology through the acquisition of Acrobot, a medical devices company specializing in computer-assisted orthopaedic surgery in August 2010. Stanmore Implants Worldwide was acquired by Stryker on April 29, 2016. It was founded in 1948 and is headquartered in London, UK.

Internis Pharmaceuticals

Debt Financing in 2013
Internis is an exciting and innovative British start-up business. Founded in 2010, it is a pharmaceutical company engaged in the development and commercialisation of highly effective and innovative new medicines aimed at the treatment and prevention of a range of common bone disorders, such as osteoporosis and vitamin D3 deficiency. Internis supplies a prescription only licensed medicine (FultiumD3) to treat patients with a vitamin D deficiency. Vitamin D is offered to at-risk groups on prescription to prevent the health risks associated with a deficiency or insufficiency. It is estimated that up to a quarter of the population in the UK have low levels of vitamin D in their blood – with deficiency linked to conditions including bone deformities and health complications such as depression, joint pain, migraines, fatigue and a weakened immune system.

SpineGuard

Venture Round in 2012
SpineGuard is a French medical company focused on the design and production of innovative instruments for spinal surgeries. Its core technology, Dynamic Surgical Guidance (DSG®), provides a powerful, radiation-free real-time sensing platform that enhances the accuracy of skeletal implant placement. The company's flagship products, PediGuard probes, are handheld tools that assist spine surgeons in creating pilot holes in vertebrae prior to pedicle screw placement. These devices utilize an electrical conductivity measurement sensor to provide immediate feedback to surgeons regarding changes in bone and tissue composition, eliminating the need for X-ray imaging. SpineGuard’s products are applicable across a range of patient demographics, from pediatric cases involving deformity corrections to adults requiring internal fixation for degenerative conditions. The PediGuard line includes various designs to accommodate different surgical needs. Additionally, the DSG® Connect App enables the collection and visualization of data during procedures. With over 80,000 successful spinal surgeries supported by its technology and significant clinical evidence affirming its effectiveness, SpineGuard is positioned to address critical challenges in spinal surgery.

Medical Vision

Debt Financing in 2012
Medical Vision AB develops, constructs, and produces medical devices used during endoscopic procedures. It offers arthro-tube products, arthroscopy pumps, arthroscopy sets, receptacles, digital camera systems, capture devices, fluid management systems, and double pumps.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.